EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome
Ann Rheum Dis. 2022. Epub ahead of print doi: 10.1136/annrheumdis-2021-221733
There is a known increased risk of cardiovascular disease in patients with inflammatory rheumatic diseases, in comparison to the general population. However, as this risk is not sufficiently explained by differences in the prevalence of traditional CVR factors, specific treatment recommendations tailored to patients with these conditions are needed.
As such, A EULAR Task Force has developed four overarching principles and 19 recommendations for the management of CVR in patients in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.